GO:0050928 negative regulation of positive chemotaxis: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050928 describes any process that stops, prevents, or reduces the directed movement of a motile cell or organism toward a higher concentration of a chemical gradient.
• Negative regulation of positive chemotaxis is essential for confining immune cells to appropriate tissues and preventing excessive inflammation.
• Key molecular brakes include the adaptor protein p66Shc, which inhibits chemokine receptor signaling and B-cell chemotaxis.
• Macrophage polarization states differentially regulate chemotaxis, with M1 macrophages promoting and M2 macrophages resolving recruitment.
• Dysregulation of this process contributes to myocardial ischemia/reperfusion injury, tumor immune evasion, and atopic disorders.
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of negative regulators in chemotaxis.
Description
Negative regulation of positive chemotaxis (GO:0050928) is a biological process that attenuates the directed migration of cells or organisms toward higher concentrations of a chemical attractant. This process is critical for immune homeostasis, as it prevents excessive or misdirected leukocyte infiltration that can lead to tissue damage. The QuickGO definition encompasses any mechanism that stops, prevents, or reduces the frequency, rate, or extent of positive chemotaxis. Researchers study this term to understand how cells integrate attractant signals with inhibitory cues to achieve precise spatial and temporal control of movement. Dysregulation of these inhibitory pathways is implicated in inflammatory diseases, cancer, and cardiovascular injury. Understanding the molecular players that negatively regulate chemotaxis provides targets for therapeutic intervention and informs the design of CRISPR-based models to probe gene function.
negative regulation of positive chemotaxis At A Glance
| GO ID | GO:0050928 |
|---|---|
| GO term | negative regulation of positive chemotaxis |
| Ontology | biological_process |
| Synonym | down regulation of positive chemotaxis, down-regulation of positive chemotaxis, downregulation of positive chemotaxis, inhibition of positive chemotaxis |
| Major function | Attenuation of directed cell migration toward chemical gradients |
| Related process | Regulation of chemotaxis, negative regulation of chemotaxis |
| Key regulators | p66Shc, PAG/CBP, BCAT2, Interleukin-34 |
| Disease relevance | Inflammation, myocardial injury, tumor immune evasion, atopic disorders |
What Is GO:0050928?
GO:0050928, negative regulation of positive chemotaxis, refers to any process that stops, prevents, or reduces the directed movement of a motile cell or organism towards a higher concentration of a specific chemical in a concentration gradient. It is a biological process that acts as a brake on chemotaxis, ensuring that cell migration is appropriately restrained in time and space.
Why Is negative regulation of positive chemotaxis Important in Cell Biology?
Negative regulation of positive chemotaxis is fundamental for immune cell trafficking, wound healing, and developmental morphogenesis. Without proper inhibitory control, cells may migrate excessively or to wrong locations, causing chronic inflammation, autoimmune reactions, or impaired pathogen clearance. This process also shapes the tumor microenvironment by limiting anti-tumor immune cell recruitment. Understanding its mechanisms can reveal therapeutic targets for inflammatory diseases, cancer, and cardiovascular disorders.
• Prevents excessive neutrophil and macrophage infiltration during inflammation.
• Regulates B-cell homing and chemokine receptor desensitization.
• Controls mast cell signaling and allergic responses.
• Modulates tumor immune microenvironment and response to immunotherapy.
• Influences myocardial ischemia/reperfusion injury by limiting macrophage recruitment.
• Contributes to primary atopic disorders and allergic inflammation.
• Essential for proper embryonic development and organogenesis.
• Provides targets for anti-inflammatory drug development.
• Helps maintain tissue homeostasis by preventing collateral damage.
• Dysregulation linked to autoimmune and chronic inflammatory diseases.
What Happens During negative regulation of positive chemotaxis?
Initiation of inhibitory signaling
In simple terms: A cell receives a stop signal that counteracts the attractant.
Negative regulation of positive chemotaxis begins when inhibitory receptors or intracellular phosphatases are engaged, often following prolonged or high-dose chemokine stimulation. For example, the adaptor protein p66Shc is recruited to chemokine receptors and initiates a signaling cascade that dampens migratory responses. This step involves phosphorylation events and recruitment of negative regulators to the leading edge.
Attenuation of chemokine receptor signaling
In simple terms: The receptor that senses the attractant is turned down.
Following activation, chemokine receptors undergo desensitization and internalization, reducing their ability to transmit pro-migratory signals. p66Shc negatively regulates chemokine receptor signaling by promoting receptor degradation or by interfering with downstream G-protein activation. This attenuation is crucial to prevent excessive B-cell chemotaxis.
Modulation of actin cytoskeleton dynamics
In simple terms: The cell's internal skeleton is reorganized to stop movement.
Inhibitory signals lead to changes in actin polymerization and depolymerization, disrupting the leading edge and reducing forward protrusion. The chemotactic compass model suggests that negative regulators act on Rho GTPases or their effectors to destabilize polarity. This results in reduced directional persistence and slower migration.
Integration with macrophage polarization states
In simple terms: Different immune cell states have different braking systems.
Macrophage polarization influences the expression of negative regulators of chemotaxis. M1 (classically activated) macrophages exhibit enhanced chemotaxis, while M2 (alternatively activated) macrophages show reduced migratory responses due to upregulation of inhibitory pathways. This differential regulation is critical for resolving inflammation.
Resolution of migration and tissue retention
In simple terms: The cell stops moving and stays put.
Ultimately, negative regulation leads to reduced frequency and rate of directed movement, causing cells to remain in tissues or lymphoid organs. This is essential for proper immune surveillance and preventing systemic dissemination of activated cells. Dysregulation can lead to chronic inflammatory diseases.
Key Genes Involved in GO:0050928 negative regulation of positive chemotaxis
The following genes and proteins have been experimentally linked to negative regulation of positive chemotaxis or related inhibitory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| p66Shc (SHC1) | Inhibits chemokine receptor signaling and B-cell chemotaxis | Key negative regulator; knockout enhances migration |
| PAG/CBP (PAG1) | Transmembrane adaptor in mast cell signaling | Both positive and negative regulation of mast cell signaling |
| BCAT2 | Negatively regulates proinflammatory chemokines | Shapes noninflamed tumor microenvironment |
| Interleukin-34 | Promotes macrophage recruitment via NF-κB | Aggravates myocardial ischemia/reperfusion injury |
| NF-κB | Transcription factor in inflammatory signaling | Mediates IL-34 effects on macrophage polarization |
| CCR7 | Chemokine receptor for CCL19/CCL21 | Regulates B-cell and dendritic cell migration |
| CXCR4 | Chemokine receptor for CXCL12 | Involved in chemotaxis and its negative regulation |
| Rho GTPases | Regulate actin cytoskeleton during migration | Targets of inhibitory signals |
| PTEN | Phosphatase that antagonizes PI3K signaling | Negative regulator of chemotaxis in some contexts |
| SHIP1 | Inositol phosphatase | Modulates chemokine signaling |
| SOCS proteins | Suppressors of cytokine signaling | Potential negative regulators of chemotaxis |
| IL-4 | Cytokine promoting M2 polarization | Induces negative regulators of chemotaxis |
| IL-13 | Cytokine promoting M2 polarization | Similar to IL-4 |
| LPS | Stimulus for M1 polarization | Enhances chemotaxis, reduces negative regulation |
| TGF-β | Immunosuppressive cytokine | May upregulate inhibitory pathways |
| PD-L1 | Immune checkpoint ligand | Linked to BCAT2-mediated chemokine regulation |
| c-di-GMP | Second messenger in bacteria | Regulates motility and chemotaxis in Pseudomonas |
How Is negative regulation of positive chemotaxis Regulated?
Negative regulation of positive chemotaxis is itself tightly regulated at multiple levels. Transcriptional control by cytokines such as IL-4 and IL-13 promotes the expression of inhibitory proteins like p66Shc and SOCS family members. Post-translational modifications, including phosphorylation and ubiquitination, modulate the stability and activity of negative regulators. In macrophages, polarization states dictate the balance between pro-migratory and inhibitory signaling, with M2 macrophages exhibiting enhanced negative regulation. Additionally, bacterial second messengers like c-di-GMP regulate chemotaxis in microorganisms, illustrating evolutionary conservation of these control mechanisms.
negative regulation of positive chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL-34 | Myocardial ischemia/reperfusion injury | Knockout mouse, overexpression in macrophages |
| BCAT2 | Tumor immune evasion, anti-PD-1 resistance | Knockout in cancer cell lines, syngeneic models |
| p66Shc | Autoimmune B-cell responses | Knockout mice, B-cell chemotaxis assays |
| PAG/CBP | Allergic inflammation, mast cell disorders | Knockout mast cells, passive cutaneous anaphylaxis |
| SHIP1 | Inflammatory diseases | Knockout mice, chemotaxis assays |
Myocardial ischemia/reperfusion injury
Interleukin-34 promotes macrophage recruitment and polarization via NF-κB signaling, aggravating myocardial ischemic/reperfusion injury. Negative regulation of chemotaxis is impaired in this context, leading to excessive macrophage infiltration and tissue damage. Targeting this pathway may reduce injury.
Cancer and tumor immune evasion
BCAT2 shapes a noninflamed tumor microenvironment by negatively regulating proinflammatory chemokines, thereby reducing anti-tumor immune cell recruitment and inducing resistance to anti-PD-1/PD-L1 immunotherapy. This highlights how negative regulation of chemotaxis can be hijacked by tumors to evade immune attack.
Primary atopic disorders
Primary atopic disorders often involve dysregulated immune cell trafficking, including defective negative regulation of chemotaxis. Rapid genomic sequencing can identify mutations in genes controlling these pathways, enabling personalized management.
Inflammatory and autoimmune diseases
Defects in negative regulators such as p66Shc lead to enhanced B-cell chemotaxis and autoantibody production, contributing to autoimmune conditions. Mast cell signaling abnormalities, including PAG/CBP dysfunction, are linked to allergic inflammation.
From negative regulation of positive chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate chemotaxis? | CRISPR knockout in primary immune cells or cell lines |
| What is the effect of a point mutation in a negative regulator? | CRISPR point mutation knock-in |
| How does a tagged version of the protein localize during chemotaxis? | CRISPR knock-in of fluorescent tag |
| Does overexpression of gene Y inhibit chemotaxis? | CRISPR overexpression (e.g., CRISPRa) |
| Which genes are essential for negative regulation? | Genome-wide CRISPR library screening |
| How does a disease-associated SNP affect chemotaxis? | CRISPR knock-in of SNP in cell lines |
How to Study the negative regulation of positive chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging | Cell migration speed, directionality, frequency | Validation of negative regulators |
| CRISPR knockout screening | Genes affecting chemotaxis | Discovery of novel regulators |
| Phosphoproteomics | Signaling changes and phosphorylation sites | Mechanistic studies |
| RNA-seq | Transcriptional profiles of polarized cells | Identifying differentially expressed inhibitory genes |
| Chemotaxis assay (Transwell) | Number of migrated cells | Quantifying positive and negative regulation |
| FRET biosensors | Rho GTPase activity dynamics | Real-time monitoring of cytoskeletal changes |
| Flow cytometry | Chemokine receptor surface expression | Receptor internalization studies |
Live-cell imaging and chemotaxis assays
Live-cell imaging using microfluidic chambers or Dunn chambers allows real-time visualization of directed migration and its inhibition. Tracking individual cell trajectories provides quantitative measures of speed, directionality, and frequency of positive chemotaxis. This method is essential for validating negative regulators identified by genetic screens.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate chemotaxis. Cells are subjected to a chemotactic gradient, and those with altered migration are sequenced to identify sgRNAs. This unbiased approach has revealed novel regulators in immune cells and cancer.
Phosphoproteomics and signaling analysis
Mass spectrometry-based phosphoproteomics can map signaling events downstream of chemokine receptors and identify phosphorylation sites on negative regulators. This helps elucidate how p66Shc and other proteins attenuate signaling. Combining with CRISPR knockouts enables causal validation.
Transcriptomic profiling of polarized macrophages
RNA-seq of M1 and M2 macrophages reveals differential expression of genes involved in negative regulation of chemotaxis. This provides insights into how polarization states control migratory capacity. Validation by qPCR and functional assays confirms the role of candidate genes.
How CRISPR Can Be Used to Study GO:0050928 negative regulation of positive chemotaxis
Knockout
CRISPR knockout of candidate negative regulators such as p66Shc or PAG/CBP allows researchers to assess whether loss of function enhances chemotaxis. This is typically achieved by delivering Cas9 and sgRNAs targeting the gene of interest into immune cells or cell lines, followed by chemotaxis assays. Knockout models have demonstrated that p66Shc deficiency leads to increased B-cell chemotaxis.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid substitutions to dissect domain functions or model disease-associated variants. For example, mutating phosphorylation sites on p66Shc can reveal their importance in negative regulation. This approach requires homology-directed repair templates and careful validation.
Knock-in
Knock-in of fluorescent tags or epitope tags into endogenous loci enables real-time tracking of negative regulator localization and interactions. Tagging proteins like PAG/CBP allows visualization of their recruitment to signaling complexes during chemotaxis. This method preserves endogenous expression levels and regulation.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression can elevate levels of negative regulators to test their sufficiency in inhibiting chemotaxis. Overexpressing p66Shc or BCAT2 in cell lines can suppress migration and alter chemokine profiles. This approach is useful for gain-of-function studies.
How EDITGENE Supports negative regulation of positive chemotaxis Research
Researchers studying negative regulation of positive chemotaxis-related genes often need to determine whether a candidate gene is causally involved in attenuating cell migration or is merely correlated with the phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of positive chemotaxis research.
Frequently Asked Questions About negative regulation of positive chemotaxis
What is negative regulation of positive chemotaxis?
It is any process that stops, prevents, or reduces the directed movement of a cell or organism toward a higher concentration of a chemical attractant, as defined by GO:0050928.
What genes are involved in negative regulation of positive chemotaxis?
Key genes include p66Shc (SHC1), PAG/CBP (PAG1), BCAT2, and Interleukin-34, among others.
How does p66Shc inhibit chemotaxis?
p66Shc negatively regulates chemokine receptor signaling and B-cell chemotaxis by attenuating downstream signaling pathways.
What diseases are linked to defective negative regulation of chemotaxis?
Myocardial ischemia/reperfusion injury, cancer immune evasion, primary atopic disorders, and autoimmune diseases.
How can CRISPR be used to study negative regulation of chemotaxis?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of candidate genes in chemotaxis assays.
What is the role of macrophage polarization in chemotaxis regulation?
M1 macrophages promote chemotaxis, while M2 macrophages enhance negative regulation, resolving inflammation.
Which signaling pathways are involved in negative regulation of chemotaxis?
NF-κB, PI3K/PTEN, Rho GTPase, and chemokine receptor desensitization pathways.
What methods are used to measure negative regulation of chemotaxis?
Live-cell imaging, Transwell assays, CRISPR screens, phosphoproteomics, and RNA-seq.
Can BCAT2 affect immune cell recruitment?
Yes, BCAT2 negatively regulates proinflammatory chemokines, reducing anti-tumor immune cell recruitment.
What is the clinical significance of Interleukin-34 in chemotaxis?
IL-34 promotes macrophage recruitment via NF-κB, aggravating myocardial ischemia/reperfusion injury.
Conclusion
Negative regulation of positive chemotaxis (GO:0050928) is a vital biological process that restrains directed cell migration to maintain immune homeostasis and prevent tissue damage. Dysregulation of this process contributes to a range of diseases, including cardiovascular injury, cancer, and allergic disorders. Advances in CRISPR-based models and functional genomics are accelerating the discovery of new regulatory mechanisms and therapeutic targets. Continued research into this process will deepen our understanding of cell migration control and open new avenues for intervention.
References
- 1. Orecchioni M et al.. 2019. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.. Front Immunol 10:1084 PMID: 31178859
- 2. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 3. Zhuang L et al.. 2023. Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.. EBioMedicine 95:104744 PMID: 37556943
- 4. Patrussi L et al.. 2014. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc.. Cell Death Dis 5(2):e1068 PMID: 24556683
- 5. Weiner OD. 2002. Regulation of cell polarity during eukaryotic chemotaxis: the chemotactic compass.. Curr Opin Cell Biol 14(2):196-202 PMID: 11891119
- 6. Wang T et al.. 2023. c-di-GMP signaling in Pseudomonas syringae complex.. Microbiol Res 275:127445 PMID: 37450986
- 7. Draberova L et al.. 2014. Transmembrane adaptor protein PAG/CBP is involved in both positive and negative regulation of mast cell signaling.. Mol Cell Biol 34(23):4285-300 PMID: 25246632
- 8. Cai Z et al.. 2023. BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.. Adv Sci (Weinh) 10(8):e2207155 PMID: 36642843
